MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

This potential treatment opportunity was confirmed by the company’s bioinformatics platform, PsyCollage

VANCOUVER, BC, March 4, 2021 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain ...

Continue Reading →
JR Rahn, Mindmed Co-Founder and Board Member

Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine


TORONTO, Sept. 16, 2019 /PRNewswire/ — Mind Medicine, Inc. (“Mindmed”), the leading neuro-pharmaceutical company focused on discovering and developing medicines based on psychedelics, has finalized the acquisition of the 18-MC drug development program, an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse (“NIDA”). Mindmed acquired the project from Savant HWP Inc., whose leadership team of top researchers and drug developers will also join ...

Continue Reading →